Toggle Main Menu Toggle Search

Open Access padlockePrints

Lynch Syndrome: History, Causes, Diagnosis, Treatment and Prevention (CAPP2 Trial)

Lookup NU author(s): Professor Sir John BurnORCiD, Professor John Mathers


Full text for this publication is not currently held within this repository. Alternative links are provided below where available.


Hereditary cancer due to pathological mutations in the mismatch repair gene family is now known as Lynch syndrome and affects at least 1 in 1,000 people, resulting in a 30-50% cancer risk most often involving the colorectum and endometrium. Annual or biennial colonoscopy reduces cancer deaths and many offer gynaecological surveillance, but most other associated cancers are not amenable to early detection. As microsatellite instability testing and tumour immunohistochemistry become routine, case finding will improve. Our recent demonstration that 600 mg aspirin per day for at least 2 years reduces the cancer burden by 63% after a 3-year lag period reinforces the need to identify gene carriers and introduce them to chemoprevention. CaPP3 will test different doses of aspirin in at least 3,000 gene carriers to determine whether low-dose aspirin is as effective. Copyright (c) 2012 S. Karger AG, Basel

Publication metadata

Author(s): Burn J, Mathers J, Bishop DT

Publication type: Article

Publication status: Published

Journal: Digestive Diseases

Year: 2012

Volume: 30

Issue: s2

Pages: 39-47

Print publication date: 01/01/2012

ISSN (print): 0257-2753

ISSN (electronic): 1421-9875

Publisher: S. Karger AG


DOI: 10.1159/000341892


Altmetrics provided by Altmetric